Low PD-L1 Expressing
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma (NCT06932068) | Qilu Hospital of Shandong University | 2025-03-26 |
Track Low PD-L1 Expressing automatically
Every clearance here is in the API, with alerts when new ones post.